Information Library

Results for: Case Studies - Faster product development

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Propelling Pediatric Research

    April 1, 2010
    Learn how Quintiles' global reach and rigorous research standards dramatically cut recruitment from 4 years to 1 in a childhood immunology study

  • Boosting Pediatric Enrollment

    April 1, 2010
    Read how Quintiles took a nasal influenza vaccine trial from the brink of delay to full recruitment in only two weeks.

  • Anticipating the Challenge

    March 3, 2010
    Extensive experience and expertise in Alzheimer's Disease accelerated outcomes in multi-country Phase II study.

  • Advancing Innovation

    March 3, 2010
    Prescreening and safety measures simplified a Phase II study of a four-dose vaccine that required multiple rating scales.

  • Multinational Coordination

    February 26, 2010
    Coordinating a non-Hodgkin’s lymphoma study across six countries, our expert team exceeded expectations for efficiency and communication.

  • Unrivalled Global Reach

    February 22, 2010
    Failure was never an option with Quintiles’ guiding this complex global chronic heart failure study.

  • Enabling Transformation

    September 30, 2009
    Biovitrum found an ideal opportunity to transform itself into a fully integrated specialty pharmaceutical company from a biotech discovery and early clinical development company.

  • Cardiovascular Expertise Results in Faster Enrollment Speed

    March 27, 2009
    Mega-trials require mega-expertise, especially when the global study is for an innovative cardiovascular drug to treat patients with acute coronary syndrome who have also undergone coronary artery bypass surgery.

  • Antibiotic Safety Assessment

    March 25, 2009
    A major pharmaceutical company presented Quintiles with a pressing challenge – to collect extensive amounts of Phase IV data in compressed time windows because the treatment conditions were subject to seasonal variants.

  • Jumpstarting a Phase III Candidate

    March 24, 2009
    A global pharmaceutical company had a promising new formulation of a marketed product in early Phase III trials, but R&D budget pressures were likely to result in delays getting the product to market.

Page 1 of 1 (10 results)

Subscribe to Email Based on Your Interests

Set preferences